• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships

    6/30/26 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email

    O'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and providers as Dario moves closer to care

    O'Reilly's track record of leveraging advanced data analytics and AI in supporting value-based care strongly aligned with Dario's AI transition

    NEW YORK, June 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-enabled digital health solutions, today announced the appointment of Sean O'Reilly to its Advisory Board. The appointment reflects Dario's continued focus on strengthening its strategic guidance as the Company advances its channel partner-led growth strategy and moves closer to care across the payer, provider and employer markets.

    DarioHealth Corp. Logo

    Mr. O'Reilly brings extensive healthcare compliance, risk management, regulatory oversight and legal experience across complex healthcare, insurance and clinical operations. He has led compliance programs supporting Medicare Advantage, Medicaid, employer group medical and specialty insurance, military healthcare, hospice and home health, value-based primary care and pharmacy benefit management organizations.

    "Sean brings an exceptional combination of healthcare compliance leadership, operational and payer industry expertise, as well as M&A experience," stated Dario's Chief Executive Officer, Erez Raphael. "His perspective will be invaluable as we continue to expand Dario's relationships across the healthcare ecosystem, accelerate adoption of our AI-powered behavioral health and chronic multi-condition management platform, and move closer to care."

    "Dario is operating in one of the most important areas of healthcare, where digital engagement, clinical impact, regulatory confidence and measurable value must come together," said Mr. O'Reilly. "The Company's platform is well aligned with the needs of health plans, providers and employers seeking scalable solutions that improve outcomes while supporting accountability and operational excellence. I look forward to working with Erez and the Dario team as the Company continues to expand its role across the healthcare ecosystem."

    Prior to consulting in a prominent Healthcare Risk Management & Advisory practice, O'Reilly spent more than 13 years at Humana, including serving as Senior Vice President and Chief Compliance Officer, where he led enterprise compliance programs across Medicare Advantage, Medicaid, employer-sponsored health plans, pharmacy benefit management, home health, hospice, military healthcare and value-based care operations.

    His experience leveraging advanced data analytics and AI to strengthen compliance oversight, operational performance and value-based care aligns closely with Dario's commitment to delivering measurable healthcare outcomes through innovative technology solutions.

    Mr. O'Reilly is also a licensed attorney with a background in mergers and acquisitions. His work integrates privacy, ethics and technology-driven risk analysis to strengthen compliance culture, support operational integrity and enable strategic growth.

    About DarioHealth Corp. (NASDAQ:DRIO)

    DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

    Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

    Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.  

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when the Company's belief that Mr. O'Reilly's experience is expected to support the Company's continued expansion with health plans, employers and providers; the Company's belief that Mr. O'Reilly's appointment will strengthen its strategic guidance; the Company's expectation to continue advancing its channel partner-led growth strategy; the Company's future adoption of its AI-powered behavioral health and chronic multi-condition management platform; the Company's expectation to continue expanding its relationships across the healthcare ecosystem; the Company's expectation to continue expanding its role across the payer, provider and employer markets; the Company's belief its platform is well aligned with the needs of health plans, providers and employers; and the Company's belief its technology will continue to support measurable healthcare outcomes. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contacts

    Michael Lipari

    SVP Corporate Development

    irteam@dariohealth.com

    +1-201-785-6310

    Rob Halpern

    SVP Marketing

    irteam@dariohealth.com

    Logo- https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

     

    Cision View original content:https://www.prnewswire.com/news-releases/dario-appoints-former-humana-chief-compliance-officer-sean-oreilly-to-advisory-board-to-support-strategic-growth-and-healthcare-partnerships-302813813.html

    SOURCE DarioHealth Corp.

    Get the next $DRIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles bought $21,200 worth of shares (40,000 units at $0.53), increasing direct ownership by 73% to 95,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    8/27/25 4:30:59 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    11/14/24 4:15:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/12/24 4:37:42 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    SEC Filings

    View All

    DarioHealth Corp. filed SEC Form 8-K: Leadership Update

    8-K - DarioHealth Corp. (0001533998) (Filer)

    7/10/26 5:10:06 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by DarioHealth Corp.

    10-Q - DarioHealth Corp. (0001533998) (Filer)

    5/13/26 6:05:57 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by DarioHealth Corp.

    SD - DarioHealth Corp. (0001533998) (Filer)

    5/7/26 4:05:07 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform

    Contract award for over 100,000 eligible employees marks Dario's fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition managementProgram expected to launch Fall 2026, with revenue contribution beginning by year-end and ramping through 2027NEW YORK, July 16, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/o

    7/16/26 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15%

    DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth for DarioDario IQ's AI-driven personalization increases member engagement by 40% and improves member retention by 20% by leveraging 13+ billion proprietary real-world healthcare data pointsNEW YORK, July 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the Company expects broader deployment of DarioIQ™, its proprietary, responsible generative and agentic AI platform, to increase annual Business-to-Business-

    7/13/26 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership

    Agreement representative of Dario's channel-led growth strategy to bring cardiometabolic digital health solution at scale to self-insured employers seeking measurable reductions in cardiometabolic risk and total cost of care via payer relationships NEW YORK, July 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced a new agreement with a major health insurer with a stronghold in Arizona, entered into through its strategic channel partnership with Amwell.  This opportunity makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only ("ASO") book of business, repre

    7/6/26 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Palumbo John R

    3 - DarioHealth Corp. (0001533998) (Issuer)

    4/13/26 4:05:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    President and CCO Nelson Steven Charles was granted 30,000 shares, increasing direct ownership by 632% to 34,750 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:04:08 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Stern Adam K was granted 20,000 shares, increasing direct ownership by 206% to 29,717 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:03:10 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth downgraded by TD Cowen with a new price target

    TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

    1/29/25 7:36:04 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

    5/13/22 9:01:42 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Aegis Capital reiterated coverage on DarioHealth with a new price target

    Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

    1/26/22 10:35:44 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships

    O'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and providers as Dario moves closer to careO'Reilly's track record of leveraging advanced data analytics and AI in supporting value-based care strongly aligned with Dario's AI transitionNEW YORK, June 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-enabled digital health solutions, today announced the appointment of Sean O'Reilly to its Advisory Board. The appointment reflects Dario's continued focus on strengthening its strategic

    6/30/26 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

    Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic valueNEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.  The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling. Mr. Palumbo brings more than 40 ye

    4/13/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

    Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

    2/27/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Financials

    Live finance-specific insights

    View All

    DarioHealth Reports First Quarter 2026 Financial and Operating Results

    First quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growthOperating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-quarterOperating loss decreased by 22% year-over-year and decreased by 15% quarter-over-quarter; Non-GAAP operating loss decreased by 8% year-over-year and decreased by 11% quarter-over-quarterChannel partnerships through Solera, Amwell and other blue-chip partners provide access to over 116 million covered livesNow in contracting phase with new channel partner that, upon finalization, would extend Dario's reach to a combined 175+ million covered lives and add one of the largest hospital networks

    5/13/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026

    Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 13th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Wednesday, May13th, 2026, 8:30 a.m. Eastern TimeDial-in Number: 1-80

    5/4/26 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-

    3/19/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    10/29/24 11:45:28 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

    SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

    2/14/24 4:51:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care